OptiPin
ARA-290: uses, dosing & the facts
ARA-290 is an 11-amino acid peptide engineered from the tertiary structure of erythropoietin (EPO). It activates the innate repair receptor to support tissue repair and nerve healing without stimulating red blood cell production. Research suggests benefits for neuropathic pain relief, small nerve fiber repair, and wound healing. This is an evidence-graded reference — what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • ARA-290 — Research peptide. ARA-290 is an 11-amino acid peptide engineered from the tertiary structure of erythropoietin (EPO).
- • Commonly used for neuropathic pain relief and nerve repair, small fiber neuropathy (e.g., diabetic neuropathy, sarcoidosis-associated), wound healing and tissue repair.
- • Half-life: Short; daily dosing is standard..
- • Status: Research use only · not FDA-approved — an educational reference, not a dose protocol or sourcing advice.
What ARA-290 is
ARA-290 is an 11-amino acid peptide engineered from the tertiary structure of erythropoietin (EPO). It activates the innate repair receptor to support tissue repair and nerve healing without stimulating red blood cell production. Research suggests benefits for neuropathic pain relief, small nerve fiber repair, and wound healing.
What ARA-290 is used for
- • Neuropathic pain relief and nerve repair
- • Small fiber neuropathy (e.g., diabetic neuropathy, sarcoidosis-associated)
- • Wound healing and tissue repair
- • Metabolic and vascular support
- • Corneal and peripheral nerve fiber recovery
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | 2–4 mg subcutaneously once daily. Clinical trials have used 4 mg daily for 28 days; 2 mg daily is also common for maintenance or wound healing. |
Presented as commonly-reported patterns for information only — not a dose recommendation. ARA-290 dosing is a decision for a qualified clinician.
Reconstitution
Reconstitute according to vial size with bacteriostatic water. Dosing is typically in milligrams (e.g., 2 mg = 0.2 mL if reconstituted at 10 mg/mL). The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Short; daily dosing is standard.. Half-life drives dosing frequency and how quickly the compound clears — see it plotted on the half-life visualizer.
Cycling
Typical courses run 4–8 weeks (e.g., 28 days in trials with sustained benefit). A break of several weeks may be used before repeating.
Side effects & warnings
- • Generally well-tolerated in clinical studies
- • Mild injection site reactions possible
Research use only. Consult a healthcare provider before use. Not intended to replace EPO for anemia.
Tracking ARA-290 in OptiPin
If you're tracking a ARA-290 protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math — all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math — all on-device.
Download on the App StoreFAQ
What is ARA-290?
ARA-290 is an 11-amino acid peptide engineered from the tertiary structure of erythropoietin (EPO). It activates the innate repair receptor to support tissue repair and nerve healing without stimulating red blood cell production. Research suggests benefits for neuropathic pain relief, small nerve fiber repair, and wound healing.
What is ARA-290 used for?
Commonly discussed uses include: neuropathic pain relief and nerve repair, small fiber neuropathy (e.g., diabetic neuropathy, sarcoidosis-associated), wound healing and tissue repair, metabolic and vascular support, corneal and peripheral nerve fiber recovery. These are reported uses, not proven outcomes or a recommendation.
How is ARA-290 dosed?
Commonly reported dosing: Injectable — 2–4 mg subcutaneously once daily. Clinical trials have used 4 mg daily for 28 days; 2 mg daily is also common for maintenance or wound healing.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation — ARA-290 is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute ARA-290?
Reconstitute according to vial size with bacteriostatic water. Dosing is typically in milligrams (e.g., 2 mg = 0.2 mL if reconstituted at 10 mg/mL). On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is ARA-290's half-life?
Short; daily dosing is standard.. Half-life shapes how often it is dosed and how quickly it clears.
What are ARA-290's side effects?
Reported effects include: generally well-tolerated in clinical studies, mild injection site reactions possible. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for ARA-290 on PubMed (entry point to the primary evidence base, not a specific citation).
- ARA-290 on ClinicalTrials.gov — registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide — categories, evidence grading, and how to run a protocol honestly.
Related
CJC-1295 (with DAC) · CJC-1295 (without DAC) · GHRP-2 · GHRP-6 · BPC-157 · TB-500 · Reconstitution calculator · All peptides